Abstract 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography–computed
tomography (PET/CT) is established for characterising indeterminate pulmonary nodules …

Tumors are highly heterogeneous entities, both morphologically and functionally. This
heterogeneity applies to the primary tumor and to systemic metastasis. The tumoral …

Background: FDG PET/CT imaging has an established role in lung cancer (LC)
management. Whilst it is a sensitive technique, FDG PET/CT has a limited specificity in the …

Increased growth and proliferation are the typical characteristic features of cancer cells, and
to maintain these processes the cells have an increased demand for energy. Adenosine …

Lung cancer is commonly affecting around three million new patients each year and is the
leading cause of cancer-related deaths in many countries. Nonsmall-cell lung carcinoma …

Ongoing technologic and therapeutic advancements in medicine are now testing the limits of
conventional anatomic imaging techniques. The ability to image physiology, rather than …

PET has seen rapid progression in recent years, with applications in oncology leading the
way. The glucose analog 18F-FDG is the most commonly used PET radiopharmaceutical …

The use of 18FDG highlights biochemical disturbations present in cancerous tissues, in
particular the accelerated glycolysis related to increased glucose transporters and to the …

Positron emission tomography (PET) using the radiopharmaceutical 18F-2-deoxy-D-glucose
(FDG), a D-glucose analog, has been shown by numerous studies to predict prognosis in …

Positron emission tomography (PET) using 18F‐2‐deoxy‐D‐glucose, a D‐glucose analog
labeled with fluorine‐18, complements conventional radiologic assessment in the evaluation …